Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02370342
Other study ID # 4K-14-3
Secondary ID NCI-2014-026364K
Status Withdrawn
Phase N/A
First received February 17, 2015
Last updated December 18, 2017
Start date December 18, 2017
Est. completion date December 18, 2019

Study information

Verified date December 2017
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial studies a type of ultrasound called robot-assisted laparoscopic high-intensity focused ultrasound for performing thermal ablative therapy, or sound wave therapy, in treating patients with small kidney masses undergoing partial removal of the kidney. The robot-assisted ultrasound probe takes images of the kidney to help doctors locate the mass. The probe then uses high frequency sound waves to target and ablate (or destroy) the kidney mass, which may be a cancerous tumor or benign tissue. Surgery is then performed to remove the part of the kidney with the mass. Robot-assisted laparoscopic high-intensity focused ultrasound for thermal ablative therapy may be safer and help doctors see the tumor better when performing kidney surgery.


Description:

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of laparoscopic high-intensity focused ultrasound (HIFU) for the treatment of localized primary renal cancer to evaluate histological accuracy in successful ablation of the small renal mass, matched with intraoperative targeting.

SECONDARY OBJECTIVES:

I. To evaluate the safety and toxicity of laparoscopic HIFU for patients with primary renal cancer.

II. To evaluate the technical success of laparoscopic HIFU ablation.

OUTLINE:

Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.

After completion of study treatment, patients are followed up at 2 days, 2 weeks, 1 month, 6 months, 12 months, and then annually for up to 3 years.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 18, 2019
Est. primary completion date December 18, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Presence of an enhancing solid renal mass =< 3.0 cm on radiological examination

- Tumors with a depth of not greater than 3.0 cm from a laparoscopically accessible surface-meaning no part of the tumor should be deeper than 3.0 cm from the surface

- Patients with solitary kidneys, bilateral renal tumors, compromised renal function (baseline creatinine > 1.4)

- Subjects must have given written informed consent

- Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgery

- Subjects must be free of any clinically significant disease other than cancer that would interfere with the study evaluations

- Absolute neutrophil count (ANC) >= 1500 mm^-3

- Platelet count >= 100,000 mm^-3

- Hemoglobin >= 10 g/dl

- Prothrombin time (PT) =< 1.5 times upper limit of laboratory normal (ULN)

- Activated partial thromboplastin time =< 1.5 times ULN

- Urea and serum creatinine < 2.5 times ULN

- Total bilirubin < 1.5 times ULN

- Aspartate aminotransferase (AST) =< 3 times ULN

- Alkaline phosphatase < 2 times ULN, unless arising from bone

Exclusion Criteria:

- < 90% solid component on screening cross-sectional imaging

- Subjects deemed unsuitable candidates and not medically optimized for partial nephrectomy

- Tumors greater than 3.0 cm at their widest point

- Subjects with tumors lying < 1 cm from sensitive structures such as the ureter, renal vessels or adjacent bowel

- Subjects on concurrent anticoagulant, or immunosuppressive medication

- Subjects on anti-cancer medication whether biologic or pharmaceutical

- Women who are pregnant or nursing (pregnancy test to be performed within 24 hours prior to HIFU treatment)

- Subjects assessed by consultant anesthetist as unsuitable for general anesthetic

- Subjects having had prior ablation therapy on the same tumor

Study Design


Intervention

Procedure:
Robot-Assisted Laparoscopic Surgery
Undergo robot-assisted laparoscopic HIFU ablation
High-Intensity Focused Ultrasound Ablation
Undergo robot-assisted laparoscopic HIFU ablation
Therapeutic Laparoscopic Surgery
Undergo laparoscopic partial nephrectomy
Device:
Sonatherm 600i Ultrasonic Lesion Generating System
Device used for high-intensity focused ultrasound ablation

Locations

Country Name City State
United States Keck Hospital of USC Los Angeles California
United States USC Norris Comprehensive Cancer Center Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
University of Southern California National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Planned ablation volume Ablation area of the kidney mass will be compared to the planned area under histopathologic review. Analyzed using a one-sided one sample T-test. Baseline (day of surgery)
Primary Necrosis volume Ablation area of the kidney mass will be compared to the planned area under histopathologic review. Analyzed using a one-sided one sample T-test. Baseline (day of surgery)
Secondary Tumor response Up to 4 years
Secondary Disease free interval From the date of treatment to the date of local or distant failure or until date of death, assessed up to 4 years
Secondary Time to local failure From the date of treatment to the time to local failure, assessed up to 4 years
Secondary Time to distant failure From the date of treatment to the time to documented metastatic disease, assessed up to 4 years
Secondary Overall success rate, measured as the combination of achieving local control of kidney cancer and demonstration of a favorable safety profile evidenced by enumeration of all adverse events by type, severity, and frequency Up to 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT04718584 - the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors Phase 2
Recruiting NCT03114826 - Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients N/A
Recruiting NCT02928692 - Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Phase 3
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Recruiting NCT03638206 - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies Phase 1/Phase 2
Recruiting NCT03786796 - Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations Phase 2
Completed NCT03064308 - The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery N/A
Not yet recruiting NCT06318871 - Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma Early Phase 1
Not yet recruiting NCT05456074 - Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)
Recruiting NCT06290427 - Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K) N/A
Recruiting NCT04773951 - A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors Phase 1